Shots:

• The approval is based on the two P-III IGNITE study assessing Xerava (eravacycline- bid- IV) vs ertapenem & meropenem in patients with cIAI
• The study demonstrated a non-inferiority data clinical response vs ertapenem with well-tolerated results and achieved high cure rates in patients with Gram-negative pathogens- including resistant isolates
• Xerava (eravacyclin- IV) is a novel fully-synthetic fluorocycline- has also received CHMP approval for CIAI in H1’18 and will be available in Q4’18

Ref: TetraPhase | Image: Twitter